uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study.

MLA

Fosbøl, Marie Øbro, et al. “UPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study.” Diagnostics (2075-4418), vol. 11, no. 6, June 2021, p. 1087. EBSCOhost, https://doi.org/10.3390/diagnostics11061087.

APA

Fosbøl, M. Ø., Mortensen, J., Petersen, P. M., Loft, A., Madsen, J., & Kjaer, A. (2021). uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study. Diagnostics (2075-4418), 11(6), 1087. https://doi.org/10.3390/diagnostics11061087

Chicago

Fosbøl, Marie Øbro, Jann Mortensen, Peter Meidahl Petersen, Annika Loft, Jacob Madsen, and Andreas Kjaer. 2021. “UPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study.” Diagnostics (2075-4418) 11 (6): 1087. doi:10.3390/diagnostics11061087.